ACP Guidance on PSA Screening Calls for Risk-Benefit Discussion, Clear Patient Preference

In recently published clinical guidance on prostate cancer screening, the American College of Physicians (ACP) calls for physicians to discuss "the limited potential benefits and substantial harms of screening for prostate cancer" with patients between the ages of 50 and 69. The guidance also encourages doctors to perform screening only if a patient expresses a clear preference to do so. According to the ACP guidance, any decision to screen using the prostate-specific antigen (PSA) test should be based on the patient's risk for prostate cancer, a discussion of the benefits and harms of screening, the patient's general health and life expectancy, and patient preferences.
Source: AAFP Health of the Public - Category: Primary Care Source Type: news